Abstract
Tuberculosis is one of the leading causes of death, with an annual mortality rate of 2 million. The present treatment regimen for Mycobacterium species is strenuous, extending up to 12 months. Even then, rise of antibiotic resistance has limited the prognosis, with increased instances of multidrug resistant (MDR–TB) and extremely drug resistant (XDR–TB) cases reported. Peptide based antibiotics can be an effective solution due to their low toxicity, biocompatibility and predictable metabolism, but has not been employed due to their short plasma half life. In this brief communication, we demonstrate the bactericidal potency of cationic amphipathic peptides as an effective bactericidal agent against Mycobacterium smegmatis. Potency of stereo-engineered LDLD or DLDL peptides have been retained their potency, while their poly L variants rapidly lost their activity, when the experiment was repeated in human serum. To establish this as a design strategy, we further verified the results by repeating the experiment in a gram negative bacteria E. coli. One of the designed peptides were showing a minimum inhibitory concentration (MIC) value as low as 3.13 µM, suggesting the possibility of future development as a therapeutic peptide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Peptide Research and Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
